Article Text

Download PDFPDF
Systematic review
Evidence is weak to support hepatocellular carcinoma screening in chronic liver disease
  1. Simon D Taylor-Robinson1,
  2. Jessica Wong2,
  3. Mary M E Crossey2,
  4. Shahid A Khan2
  1. 1Department of Medicine, Imperial College London, London, UK;
  2. 2Imperial College London, London, UK
  1. Correspondence to: Professor Simon D Taylor-Robinson, Department of Medicine, 10th Floor QEQM Wing, St Mary's Hospital Campus, Imperial College London, South Wharf Street, London W2 1NY, UK; s.taylor-robinson{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMedWeb of Science


Ninety per cent of hepatocellular carcinomas (HCCs) arise from chronic liver disease. Most cases occur in sub-Saharan Africa and Far East Asia, where chronic hepatitis B and C virus infections (HBV and HCV) are the most important risk factors. Excessive alcohol consumption and increasing obesity mean that in the developed world, HCC is also rising steadily.1 In many countries the prognosis for patients with HCC is poor, with 5-year survival rates of less than 5%. In sub-Saharan Africa, the outlook is dismal owing to late …

View Full Text


  • Competing interests None.

  • Provenance and peer review Commissioned; internally peer reviewed.